sponsored by Nibrt
October 23 2019 | 3pm BST
Presenter: Dr Roisin O’Flaherty
A report on the first large-scale comparison of glycoanalytical techniques for mAb characterization in industry and academia.
The production of monoclonal antibodies as biologic drugs has expanded dramatically. Associated with this trend has been a sudden increase in the number of laboratories determining a critical and heterogeneous property of these drugs, namely their glycosylation. This, in turn, has led to a proliferation of analysis methods, including high performance liquid chromatography (HPLC), capillary electrophoresis (CE) and mass spectrometry (MS)-based. The comparability of variety of these methods, especially as they vary lab-to-lab, presents a major challenge in understanding the meaning and accuracy of these measurements. Consequently, a large interlaboratory study was conducted by NIST to determine measurement variability in identifying and quantifying N-glycans of a NIST reference material, NISTmAb, across laboratories from 73 laboratories worldwide. The results will be presented.
Enjoy our FREE content!
Log in or register to gain full unlimited access to all content on the The Medicine Maker site. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.